在马来西亚奥密克戎变异株演变背景下评估第四剂COVID-19疫苗对住院的相对疫苗有效性:一项模拟目标试验
该研究采用模拟目标试验设计,纳入马来西亚241,434名已接种至少三剂且无既往SARS-CoV-2感染记录的18岁以上成年人,评估第四剂COVID-19疫苗相比第三剂在奥密克戎BA.4/BA.5/XBB波期间对住院的相对有效性。结果显示,在360天观察期内第四剂相比第三剂未显著降低COVID-19住院或死亡,但第四剂后90天内对住院有显著保护作用(HR=0.77;95%CI:0.35,0.92;p=0.01)。
要点
- 第四剂相比第三剂在360天内未显著降低COVID-19住院或死亡。
- 第四剂后90天内对住院有显著保护作用(HR=0.77;95%CI:0.35,0.92;p=0.01)。
- 60岁及以上人群住院减少呈非显著趋势。
核心结论
- 第四剂COVID-19疫苗(主要为单价mRNA疫苗,原始株BNT162b2)对COVID-19住院的有效性具有时间限制,短期获益后保护力在360天时减弱。
研究设计与样本
- 采用模拟目标试验设计,使用疫苗接种人群数据,纳入马来西亚241,434名已接种至少三剂且无既往SARS-CoV-2感染记录的18岁以上成年人,主要结局为COVID-19住院,死亡为次要结局,采用倾向评分匹配和含时变干预的Cox比例风险模型分析。
主要发现
- 在241,434名参与者中,360天观察期内第四剂相比第三剂未显著降低COVID-19住院或死亡。
- 第四剂后90天内对住院有显著保护作用(HR=0.77;95%CI:0.35,0.92;p=0.01)。
- 亚组分析显示60岁及以上人群住院减少呈非显著趋势。
临床怎么用
- 作者指出这些发现对具有多样化基础免疫方案的国家有意义,并强调需要持续监测疫苗有效性及采取适应性方法优化疫苗接种策略。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The emergence of new COVID-19 variants necessitates continuous evaluation of vaccine effectiveness to guide evolving vaccine strategies. This study assessed the relative effectiveness of a fourth COVID-19 vaccine dose compared to a third dose in Malaysia during the Omicron BA.4/BA.5/XBB wave. METHODS: A target trial emulation design was employed using data from the vaccinated population. Malaysian adults aged 18 and above who had received at least three vaccine doses and had no prior documented SARS-CoV-2 infection were included. The primary outcome was COVID-19 hospitalization, with death as a secondary outcome. Propensity score matching and Cox proportional hazard models with time-varying intervention were utilized for analysis. FINDINGS: Among 241,434 participants, no significant reduction in COVID-19 hospitalizations or deaths was observed with the fourth dose compared to the third dose over a 360-day period. However, a significant protective effect against hospitalization was seen within 90 days post-fourth dose (HR = 0·77; 95 % CI: 0·35, 0·92; p = 0·01). Subgroup analysis revealed a non-significant trend towards reduced hospitalizations among individuals 60 and above. INTERPRETATIONS: This study demonstrates the time-limited effectiveness of a fourth dose COVID-19 vaccine (second booster), predominantly the monovalent mRNA (original-strain BNT162b2) vaccine, against COVID-19 hospitalization. While short-term benefits were observed, protection diminished by 360 days. These findings are relevant for countries with diverse primary vaccination schemes and highlight the need for ongoing monitoring of vaccine effectiveness and adaptive approaches to optimise vaccination strategies. FUNDING: None.
引用
- Jayaraj VJ, Husin M, Tok PSK, et al. Assessing the relative vaccine effectiveness of a fourth COVID-19 dose on hospitalization in Malaysia amidst evolving omicron variants: An emulated target trial. Vaccine. 2025. PMID: 40780091. doi:10.1016/j.vaccine.2025.127569
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。